Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Galmed Pharmaceuticals: Q3 Earnings Snapshot

Galmed Pharmaceuticals: Q3 Earnings Snapshot

GLMD : 3.05 (-0.65%)
MarketBeat Week in Review – 9/16 - 9/20

Stocks got a boost as the Federal Reserve cut interest rates, but investors should expect more volatility as economic data continues to deliver mixed signals

NVDA : 134.70 (+3.08%)
GOOGL : 191.41 (+1.54%)
AAPL : 254.49 (+1.88%)
MU : 90.12 (+3.48%)
ZG : 73.77 (+2.97%)
COIN : 278.71 (+1.75%)
DAL : 60.93 (+0.91%)
ASTS : 22.88 (-0.52%)
MSFT : 436.60 (-0.10%)
SHOP : 108.95 (+1.76%)
BYND : 3.55 (+4.11%)
MA : 528.03 (+0.91%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
MRK : 98.05 (-1.48%)
NVS : 97.11 (+0.35%)
ONC.TO : 1.19 (-9.16%)
GLMD : 3.05 (-0.65%)
PFE : 26.36 (+2.29%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

ONCY : 0.8310 (-6.36%)
MRK : 98.05 (-1.48%)
NVS : 97.11 (+0.35%)
ONC.TO : 1.19 (-9.16%)
GLMD : 3.05 (-0.65%)
PFE : 26.36 (+2.29%)
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion?

Galmed Pharmaceuticals (NASDAQ: GLMD) stock skyrocketed nearly 400%, trading over 80 million shares, compared to its average of 75,000.

GLMD : 3.05 (-0.65%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 1.0400 (-48.00%)
GLMD : 3.05 (-0.65%)
VKTX : 42.25 (+1.83%)
ETNB : 7.94 (+12.94%)
IVA : 2.35 (-0.84%)
SGMT : 4.95 (-2.37%)
TERN : 5.86 (-3.14%)
NVO : 85.00 (-17.83%)
IQV : 197.27 (+3.00%)
MDGL : 308.44 (+5.12%)
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 3.05 (-0.65%)
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

/PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 3.05 (-0.65%)
Galmed Pharmaceuticals: Q2 Earnings Snapshot

Galmed Pharmaceuticals: Q2 Earnings Snapshot

GLMD : 3.05 (-0.65%)
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 3.05 (-0.65%)

Barchart Exclusives

How To Profit From The Latest Corporate Spinoffs: A Guide For Investors In 2025
How to navigate corporate spinoffs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar